Incannex Healthcare Inc. Other Finance Income Cost
Incannex Healthcare Inc. (IXHL) reported Other Finance Income Cost of $1.13 million for the 6-month period ending 2022-12-31, per its 6-K filed 2023-02-27.
Discontinued › Expense Statement › Operating Expenses
ifrs-full:OtherFinanceIncomeCost · last filed 2023-02-27
| Period end | Other Finance Income Cost 6 month | Other Finance Income Cost 12 month |
|---|---|---|
| 2022-12-31 | $1.13M 6-K · filed 2023-02-27 | |
| 2022-06-30 | $788.65K 20-F · filed 2022-10-28 | |
| 2021-12-31 | $783.29K 6-K · filed 2023-02-27 | |
| 2021-06-30 | $75.75K 20-F · filed 2022-10-28 | |
| 2020-06-30 | $217.17K 20-F · filed 2022-10-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |
| VERU INC. (VERU) | United States | $0.043B | -3.93 |
| Actinium Pharmaceuticals, Inc. (ATNM) | United States | $0.038B | 2.73 |
| FILANA THERAPEUTICS, INC. (FLNA) | United States | $0.038B | -1.05 |
| PMGC Holdings Inc. (ELAB) | United States | $0.037B | |
| BriaCell Therapeutics Corp. (BCTX) | $0.037B |